Biogen expands its modality toolkit in Alzheimer’s and Parkinson’s with Sangamo deal
With Sangamo’s zing finger technology, Biogen hopes to halt expression of neurodegeneration targets
In its latest CNS partnership, Biogen is doubling down on targets already in its pipeline with a gene regulation technology from Sangamo it hopes will shut down target expression altogether.
By closing off target expression, the company takes a different, possibly complementary, approach to treating Alzheimer’s disease (AD) and Parkinson’s disease, where the prevailing strategy is to block proteins from exerting their toxic effects.
Biogen Inc. (NASDAQ:BIIB) is stacking up on different modalities, with different risk profiles and probabilities of success, suggesting it